274 related articles for article (PubMed ID: 35881279)
21. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
23. Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment.
Ashina H; Newman L; Ashina S
Neurol Sci; 2017 Dec; 38(12):2089-2093. PubMed ID: 28856479
[TBL] [Abstract][Full Text] [Related]
24. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
Arca K; Reynolds J; Sands KA; Shiue HJ
Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
[No Abstract] [Full Text] [Related]
25. The role of anti-CGRP antibodies in the pathophysiology of primary headaches.
Barbanti P; Aurilia C; Fofi L; Egeo G; Ferroni P
Neurol Sci; 2017 May; 38(Suppl 1):31-35. PubMed ID: 28527063
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
Membrilla JA; Torres-Ferrus M; Alpuente A; Caronna E; Pozo-Rosich P
Headache; 2022 Nov; 62(10):1395-1405. PubMed ID: 36321947
[TBL] [Abstract][Full Text] [Related]
27. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
Dodick DW; Goadsby PJ; Lucas C; Jensen R; Bardos JN; Martinez JM; Zhou C; Aurora SK; Yang JY; Conley RR; Oakes T
Cephalalgia; 2020 Aug; 40(9):935-948. PubMed ID: 32050782
[TBL] [Abstract][Full Text] [Related]
29. Current advances in the management of cluster headaches.
Mavridis T; Breza M; Deligianni C; Mitsikostas DD
Expert Opin Pharmacother; 2021 Oct; 22(14):1931-1943. PubMed ID: 33989098
[No Abstract] [Full Text] [Related]
30. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial.
Vollesen ALH; Snoer A; Beske RP; Guo S; Hoffmann J; Jensen RH; Ashina M
JAMA Neurol; 2018 Oct; 75(10):1187-1197. PubMed ID: 29987329
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
32. Developments in targeting calcitonin gene-related peptide.
Alabbad S; Figueredo N; Yuan H; Silberstein S
Expert Rev Neurother; 2024 May; 24(5):477-485. PubMed ID: 38557226
[TBL] [Abstract][Full Text] [Related]
33. Fremanezumab for the prevention of chronic and episodic migraine.
Lionetto L; Cipolla F; Guglielmetti M; Martelletti P
Drugs Today (Barc); 2019 Apr; 55(4):265-276. PubMed ID: 31050694
[TBL] [Abstract][Full Text] [Related]
34. Reducing Episodic Cluster Headaches: Focus on Galcanezumab.
Pellesi L; De Icco R; Al-Karagholi MA; Ashina M
J Pain Res; 2020; 13():1591-1599. PubMed ID: 32753938
[TBL] [Abstract][Full Text] [Related]
35. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
36. Fremanezumab for the preventive treatment of migraine in adults.
Lionetto L; Curto M; Cisale GY; Capi M; Cipolla F; Guglielmetti M; Martelletti P
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):741-748. PubMed ID: 31220963
[No Abstract] [Full Text] [Related]
37. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
Lamas Pérez R; Millán-Vázquez M; González-Oria C
Cephalalgia; 2024 Mar; 44(3):3331024231226181. PubMed ID: 38501892
[TBL] [Abstract][Full Text] [Related]
39. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
40. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
